Related Experiment Video

Updated: Jun 22, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K

Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel,

Jennifer H S Küster1, Holger H H Erb2, Hannes Ahrend3

  • 1Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany.

Anticancer Research
|June 26, 2024
PubMed
Abstract

Insights

Abiraterone and enzalutamide decrease heat shock protein 27 (HSP27) in prostate cancer cells. Docetaxel and cabazitaxel do not alter HSP27, suggesting combination therapy potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Heat shock protein 27 (HSP27) is a cytoprotective protein involved in prostate cancer progression.
  • HSP27 functions as a protein chaperone, antioxidant, and apoptosis regulator.
  • HSP27 plays a role in cytoskeletal remodeling within prostate cancer cells.

Purpose of the Study:

  • To evaluate the impact of common prostate cancer therapeutics on HSP27 levels.
  • To identify potential combination therapies involving HSP27 inhibitors.

Main Methods:

  • Cell proliferation was assessed using cell counting assays.
  • Protein level changes, specifically HSP27, were analyzed via western blot.

Main Results:

  • Abiraterone, cabazitaxel, docetaxel, and enzalutamide reduced proliferation in LNCaP and PC3 cells.
  • Abiraterone and enzalutamide significantly decreased HSP27 protein levels.
  • Cabazitaxel and docetaxel did not alter HSP27 protein levels.

Conclusions:

  • Abiraterone and enzalutamide reduce HSP27 in an androgen receptor-independent manner, potentially overcoming resistance.
  • Docetaxel and cabazitaxel do not affect HSP27 levels, indicating a potential for enhanced efficacy when combined with HSP27 inhibitors.
  • Combination therapy with HSP27 inhibitors may improve outcomes for taxane-based treatments in prostate cancer.
Keywords:
HSP27HSPB1PCaandrogen receptor signalingchemoresistance

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K